CSTL (Castle Biosciences) Construction In Progress: $12.6 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSTL Castle Biosciences Inc CSTL
80 GF Score
Price $32.01
GF Value $29.71
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences Construction In Progress?

Castle Biosciences CSTL +5.12% 80 Construction In Progress is $12.6 Mil as of Jun. 2026. GuruFocus rates CSTL with a GF Score™ of 80/100 and a GF Value™ of $29.71 (Fairly Valued). The stock has 4 warning signs investors should review.

Castle Biosciences's quarterly construction in progress declined from Dec. 2025 ($51.1 Mil) to Mar. 2026 ($10.8 Mil) but then increased from Mar. 2026 ($10.8 Mil) to Jun. 2026 ($12.6 Mil).

Castle Biosciences's annual construction in progress increased from Dec. 2023 ($0.6 Mil) to Dec. 2024 ($9.6 Mil) and increased from Dec. 2024 ($9.6 Mil) to Dec. 2025 ($51.1 Mil).

Castle Biosciences Construction In Progress Historical Data

* Premium members only.

The historical data trend for Castle Biosciences's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Castle Biosciences Construction In Progress Chart

Castle Biosciences Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Construction In Progress
Get a 7-Day Free Trial Premium Member Only 0.03 1.28 0.64 9.61 51.06

Castle Biosciences Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 31.87 38.81 51.06 10.75 12.58
CSTL
80GF Score
Castle Biosciences Inc CSTL
Construction In Progress is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Castle Biosciences Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of $12.6 Mil mean?
Castle Biosciences (CSTL) has a Construction In Progress of $12.6 Mil as of Jun. 2026. Construction in Progress records the amount of construction work that is not complete. View historical data on Castle Biosciences and its competitors.
Is Castle Biosciences' Construction In Progress too high?
Castle Biosciences' current Construction In Progress is $12.6 Mil. Overall, Castle Biosciences has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' Construction In Progress compare to OPK and FLGT?
Castle Biosciences' Construction In Progress of $12.6 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Medical Diagnostics & Research company?
A good Construction In Progress depends on the Medical Diagnostics & Research industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current Construction In Progress is $12.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Fairly Valued. The stock's GF Value™ is $29.71, compared to a current price of $32.01 — trading 7.7% above its estimated fair value. The current Construction In Progress is $12.6 Mil. Castle Biosciences' overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current Construction In Progress is $12.6 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be overvalued. The current stock price of $32.01 is trading 7.7% above its estimated GF Value™ of $29.71. GuruFocus considers Castle Biosciences to be Fairly Valued.

Key valuation signals for CSTL:

  • Construction In Progress: $12.6 Mil
  • GF Value™: $29.71 vs. price of $32.01 (7.7% above fair value)
  • GF Score™: 80/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
80GF Score

Get the complete analysis for CSTL

Construction In Progress is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$32.01
Price
$29.71
GF Value